The role of NSAIDs in colon cancer prevention

Hepato-Gastroenterology

Volumn 54, Issue 78, 2007, Pages 1694-1700

  Antonakopoulos, Nikolaos ^a,b   Karamanolis, D G ^a  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b NONE   (Greece)

Author keywords

Colon cancer; COX 2; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SULINDAC;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; COLON POLYPOSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FOLLOW UP; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; APOPTOSIS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; DINOPROSTONE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PPAR DELTA;

EID: 35948956311     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2004.
2. Boolbol SK, Dannenberg AJ, Chadburn A, et al: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996; 56:2556-2560.
3. Min/+ mice. Prostaglandins Leukot Essent Fatty Acids 2000; 62:269-275.
4. Mahmoud NN, Dannenberg AJ, Mestre J, et al: Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124:225-231.
5. Ritland SR, Gendler SJ: Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis (Lond.) 1999; 20:51-58.
6. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000; 60:5040-5044.
7. Nakatsugi S, Fukutake M, Takahashi M, et al: Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 1997; 88:1117-1120.
8. Gridley G, McLaughlin JK, Ekbom A, et al: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307-311.
9. Langman MJS, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320:1642-1646.
10. Gann PH, Manson JE, Glynn RJ, Burling JE, Hennekens CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85:1220-1224.
11. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al: Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47-55.
12. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al: Aspirin and the risk of colorectal cancer in women. New Engl J Med 1995; 333:609-614.
13. Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325:1593-1596.
14. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121:241-246.
15. Garcia-Rodriguez LA, Huerta-Alvarez C: Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflamatory drugs. Epidemiology 2001; 12:88-93.
16. Jacobs EJ, Thun MJ, Bain EB, et al: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl Cancer Inst 2007; 99:608-615.
17. Suleiman S, Rex DK, Sonnenberg A: Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002; 122:78-84.
18. Sandler RS, Halabi S, Baron JA, et al: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348:883-890.
19. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313-1316.
20. Steinbach G, Lynch PM, Phillips RKS, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
21. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
22. DuBois RN, Radhika A, Reddy BS, et al: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumours. Gastroenterology 1996; 110:1259-1262.
23. Williams CS, Luongo C, Radhika A, et al: Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996; 111:1134-1140.
24. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in APC 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-809.
25. Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94:3336-3340.
26. Chapple KS, et al: Localization of cyclooxygenase-2 in human sporadic colorectal adenoma. Am J Pathol 2000; 156:545-553.
27. Vogiagis D, Brown W, Glaire E, O'Brien P: Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels. Carcinogenesis 2001; 22:869-874.
28. Brown W, Skinner S, Malcontenti-Wilson C, Vogiagis D, O'Brien P: Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation. Gut 2001; 48:660-666.
29. Vogiagis D, Glaire E, Misajon A, Brown W, O'Brien P: Cyclooxygenase-1 and an alternative spliced mRNA in the rat stomach: effects of aging and ulcers. Am J Physiol 2000; 278:820-827.
30. Min/+ mice. Cancer Res 2002; 62:403-408.
31. 1 in colon carcinogenesis. Cancer Res 1999; 59:5093-5096.
32. Morimoto K, Sugimoto Y, Katsuyama M, et al: Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract. Am J Physiol 1997; 272:681-687.
33. Inaba A, Uchiyama T, Oka M: Role of Prostaglandin E2 in rat colon carcinoma. Hepatogastroenterology 1999; 46:2347-2351.
34. Sheng H, Shao J, Washington M. Kay, DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276:18075-18081.
35. Yao R, Cooper, GM: Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995; 267:2003-2006.
36. Osada M, Tolkacheva T, Li W, et al: Differential Roles of Akt, Rac, and Ral in R-Ras-Mediated Cellular Transformation, Adhesion, and Survival. Mol Cell Biol 1999; 19:6333-6344.
37. Murga C, Fukuhara S, Gutkind JS: A novel role for phosphatidylinositol 3-kinaseβ in signaling from G protein-coupled receptors to Akt. J Biol Chem 2000; 275:12069-12073.
38. Min/+ mice. J Nutr 2000; 130:1153-1158.
39. Chan TA, Morin PJ, Vogelstein B, et al: Mechanisms underlying nonsteroidal antiinflammatory drug mediated apoptosis. Proc Natl Acad Sci USA 1998; 95:681-686.
40. Kishimoto Y, Yashima K, Morisawa T, et al: Effects of long-term administration of sulindac on APC mRNA and apoptosis in colons of rats treated with azoxymethane. J. Cancer Res. Clin Oncol 2002; 128:589-595.
41. Strauss M, Lukas J, Bartek J: Unrestricted cell cycling and cancer. Nat Med 1995; 1:1245-1246.
42. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43:527-550.
43. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 1997; 94:4312-4317.
44. Lim H, Gupta RA, Paria BC, et al: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPAR. Genes Dev 1999; 13:1561-1574.
45. Spiegelman BM: PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47:507-514.
46. Peters JM, Cattley RC, Gonzalez FJ: Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997; 18:2029-2033.
47. Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. M & Eng, C Mol Cell 1999; 3:799-804.
48. Powell SM, Zilz N, Beazer-Barclay Y, et al: APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359:235-237.
49. Aberle H, Schwartz H, Kemler R: Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996; 61:514-523.
50. Korinek V, Barker N, Morin PJ, et al: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275:1784-1787.
51. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-1512.
52. Tetsu O, McCormick F: β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398:422-426.
53. Crawford HC, Fingleton BM, Rudolph-Owen, LA, et al: The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999; 18:2883-2891.
54. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs. Cell 1999; 99:335-345.
55. Gupta R, Tan J, Krause WF, et al: Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. PNAS 2000; 97:13275-13280.
56. Muerakami K, Bujo H, Unoki H, Saito Y: Effect of PPA-Ralpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes. Eur J Pharmacol 2007; 561(1-3):206-213.
57. Suehiro T, Matsumata T, Shikada Y, Sugimachi K: Hyperinsulinemia in patients with colorectal cancer. Hepatogastroenterology 2005; 52(61):76-78.
58. Yancopoulos GD, Davis S, Gale NW, Rudge JS, et al: Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
59. Dormond O, Ruegg C: Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives. Drug Resistant Updates 2001; 4:314-321.
60. Williams CS, Tsujii M, Reese J, et al: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105:1589-1594.
61. Murohara T, Horowitz JR, Silver M, Tsurumi Y, et al: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97:99-107.
62. Daniel TO, Lieu H, Morrow JD, Crews BC, et al: Thromboxane A2 is a mediator of cyclooxygenase-2 dependent endothelial migration and angiogenesis. Cancer Res 1999; 59:4574-4577.
63. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569-571.
64. Dormond O, Foleti A, Paroz C, Ruegg C: NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001; 7:1041-1047.